Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06226714 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study completion date: Jun 2025 to Aug 2025v4
  2. Primary completion date changed from estimate of Oct 2024 to Sep 26, 2024
    • Study completion date: Oct 2024 to Jun 2025
    v3
  3. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Mar 2024 to Mar 1, 2024
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, observer-blind, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio. Subjects were required to complete a 1-dose immunization program with 0.5 ml of vaccine in both the test and control groups.
Trial Details
NCT Number NCT06226714
Lead Sponsor CanSino Biologics Inc.
Conditions
(from sponsor)		 Meningococcal Meningitis
Related terms Meningitis, Meningococcal
Enrollment 840 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov